Extracellular Vesicles (EVs) Derived from Senescent Endothelial Cells Promote Platelet Activation

Area of Science:

• Cardiovascular Biology
• Cancer Therapy
• Cellular Senescence

Background:

• Thrombotic cardiovascular diseases are common side effects of cytotoxic chemotherapy, like Doxorubicin.
• Endothelial cell senescence and its associated secretory phenotype (SASP) are implicated in chemotherapy-induced endothelial dysfunction.
• Extracellular vesicles (EVs) released by senescent cells may contribute to altered tissue microenvironments, but their role in platelet activation is unclear.

Purpose of the Study:

• To investigate the role of extracellular vesicles (EVs) from Doxorubicin-induced senescent endothelial cells in platelet activation.
• To determine if EVs from senescent endothelial cells contribute to the pro-thrombotic state.

Main Methods:

• Human microvascular endothelial cells (HMEC-1) were exposed to Doxorubicin to induce senescence.
• EVs were isolated from senescent and non-senescent HMEC-1 cells.
• EV concentration, size distribution, and platelet activation potential were analyzed.

Main Results:

• Doxorubicin-treated HMEC-1 cells exhibited senescence, endothelial dysfunction, and released EVs.
• No significant differences in EV concentration or size were observed between senescent and non-senescent cells.
• EVs from senescent cells significantly enhanced platelet activation compared to controls, though they did not induce aggregation alone.

Conclusions:

• Extracellular vesicles derived from senescent endothelial cells promote platelet activation.
• This EV-mediated platelet activation may contribute to the increased risk of thrombosis in patients undergoing Doxorubicin chemotherapy.
• Combined effects of EVs and soluble factors may be necessary for full platelet-dependent hemostasis.